IDEAYA Biosciences, Inc. Investing Cash Flow
IDEAYA Biosciences, Inc. (IDYA) reported Investing Cash Flow of -$36.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04
- IDEAYA Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$155.93M, a 439.59% decline year-over-year.
- IDEAYA Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $118.95M, a 49.03% increase year-over-year.
- IDEAYA Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$97.53M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $41.77M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $69.98M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$502.56M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$158.46M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$33.40M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$155.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$36.98M 10-Q · filed 2026-08-04 | -$134.51M derived: sum of 3 quarters · filed 2026-08-04 | -$92.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $118.95M 10-Q · filed 2026-05-05 | $21.43M derived: sum of 2 quarters · filed 2026-05-05 | $63.19M derived: sum of 3 quarters · filed 2026-05-05 | $109.11M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$97.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$55.76M derived: sum of 2 quarters · filed 2026-02-17 | -$9.84M derived: sum of 3 quarters · filed 2026-08-04 | $69.98M 10-K · filed 2026-02-17 |
| 2025-09-30 | $41.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $87.69M derived: sum of 2 quarters · filed 2026-08-04 | $167.50M 10-Q · filed 2025-11-04 | -$29.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $45.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $125.73M 10-Q · filed 2026-08-04 | -$71.37M derived: sum of 3 quarters · filed 2026-08-04 | -$91.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $79.82M 10-Q · filed 2026-05-05 | -$117.29M derived: sum of 2 quarters · filed 2026-05-05 | -$137.33M derived: sum of 3 quarters · filed 2026-05-05 | -$68.77M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$197.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$217.15M derived: sum of 2 quarters · filed 2026-02-17 | -$148.59M derived: sum of 3 quarters · filed 2026-02-17 | -$502.56M 10-K · filed 2026-02-17 |
| 2024-09-30 | -$20.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $48.52M derived: sum of 2 quarters · filed 2025-11-04 | -$305.45M 10-Q · filed 2025-11-04 | -$417.39M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $68.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$285.41M 10-Q · filed 2025-08-05 | -$397.36M derived: sum of 3 quarters · filed 2026-02-17 | -$346.01M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$353.97M 10-Q · filed 2025-05-06 | -$465.91M derived: sum of 2 quarters · filed 2026-02-17 | -$414.57M derived: sum of 3 quarters · filed 2026-02-17 | -$535.95M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | -$111.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$60.60M derived: sum of 2 quarters · filed 2026-02-17 | -$181.98M derived: sum of 3 quarters · filed 2026-02-17 | -$158.46M 10-K · filed 2026-02-17 |
| 2023-09-30 | $51.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$70.03M derived: sum of 2 quarters · filed 2024-11-04 | -$46.51M 10-Q · filed 2024-11-04 | -$56.79M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$121.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$97.86M 10-Q · filed 2024-08-06 | -$108.14M derived: sum of 3 quarters · filed 2025-02-18 | -$126.82M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $23.52M 10-Q · filed 2024-05-07 | $13.24M derived: sum of 2 quarters · filed 2025-02-18 | -$5.44M derived: sum of 3 quarters · filed 2025-02-18 | $7.88M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | -$10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$28.96M derived: sum of 2 quarters · filed 2025-02-18 | -$15.64M derived: sum of 3 quarters · filed 2025-02-18 | -$33.40M 10-K · filed 2025-02-18 |
| 2022-09-30 | -$18.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$5.37M derived: sum of 2 quarters · filed 2023-11-07 | -$23.13M 10-Q · filed 2023-11-07 | -$23.54M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $13.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$4.45M 10-Q · filed 2023-08-10 | -$4.86M derived: sum of 3 quarters · filed 2024-02-20 | -$61.16M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$17.76M 10-Q · filed 2023-05-09 | -$18.17M derived: sum of 2 quarters · filed 2024-02-20 | -$74.48M derived: sum of 3 quarters · filed 2024-02-20 | -$123.86M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$413.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$56.72M derived: sum of 2 quarters · filed 2024-02-20 | -$106.10M derived: sum of 3 quarters · filed 2024-02-20 | -$69.67M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$56.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$105.69M derived: sum of 2 quarters · filed 2022-11-08 | -$69.25M 10-Q · filed 2022-11-08 | -$73.81M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | -$49.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$12.95M 10-Q · filed 2022-08-15 | -$17.50M derived: sum of 3 quarters · filed 2023-03-07 | -$201.08M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $36.44M 10-Q · filed 2022-05-10 | $31.88M derived: sum of 2 quarters · filed 2023-03-07 | -$151.70M derived: sum of 3 quarters · filed 2023-03-07 | -$120.71M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | -$4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$188.14M derived: sum of 2 quarters · filed 2023-03-07 | -$157.15M derived: sum of 3 quarters · filed 2023-03-07 | -$146.24M 10-K · filed 2023-03-07 |
| 2020-09-30 | -$183.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$152.59M derived: sum of 2 quarters · filed 2021-11-15 | -$141.69M 10-Q · filed 2021-11-15 | -$137.80M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-06-30 | $30.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $41.89M 10-Q · filed 2021-08-10 | $45.78M derived: sum of 3 quarters · filed 2022-03-18 | $7.34M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-03-31 | $10.91M 10-Q · filed 2021-05-10 | $14.79M derived: sum of 2 quarters · filed 2022-03-18 | -$23.65M derived: sum of 3 quarters · filed 2022-03-18 | -$12.24M derived: sum of 4 quarters · filed 2022-03-18 |
| 2019-12-31 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$34.55M derived: sum of 2 quarters · filed 2022-03-18 | -$23.14M derived: sum of 3 quarters · filed 2022-03-18 | $2.27M 10-K · filed 2022-03-18 |
| 2019-09-30 | -$38.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$27.03M derived: sum of 2 quarters · filed 2020-11-12 | -$1.62M 10-Q · filed 2020-11-12 | $4.95M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | $11.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $36.82M 10-Q · filed 2020-08-12 | $43.40M derived: sum of 3 quarters · filed 2021-03-23 | $48.66M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | $25.41M 10-Q · filed 2020-05-12 | $31.98M derived: sum of 2 quarters · filed 2021-03-23 | $37.24M derived: sum of 3 quarters · filed 2021-03-23 | |
| 2018-12-31 | $6.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $11.84M derived: sum of 2 quarters · filed 2021-03-23 | -$63.18M 10-K · filed 2021-03-23 | |
| 2018-09-30 | $5.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$69.75M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | -$75.02M 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | -$8.93M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |